SkinCure Oncology Celebrates Skin Cancer Awareness Month

15 Peer-Reviewed Studies Underscore the Efficacy of a Nonsurgical Treatment Option for Nonmelanoma Skin Cancer

BURR RIDGE, Ill., April 29, 2025 /PRNewswire-PRWeb/ — SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, encourages everyone to learn how to prevent, detect and treat the nation’s most common cancer, nonmelanoma skin cancer, during Skin Cancer Awareness Month this May.

“Patients should know that if they are diagnosed with skin cancer – and some 9,500 Americans are diagnosed every day – there is a nonsurgical treatment option with an extremely high cure rate,” says SkinCure Oncology Chief Executive Officer Kerwin Brandt. “Our goal is to ensure that every person receiving a skin cancer diagnosis is fully informed of all proven treatment options, including Image-Guided SRT.”

Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells. For patients treated with Image-Guided SRT, the cure rate (freedom from recurrence at six years) has been shown to be greater than 99 percent, with researchers reporting that for early-stage nonmelanoma skin cancer, Image-Guided SRT is a clinically equivalent alternative to Mohs surgery and statistically significant in superiority to non-Image-Guided SRT.

Brandt added, “Fifteen published, peer-reviewed clinical research studies, as well as a recently published consensus document by six nationally recognized skin cancer experts, confirm that ‘IGSRT is a safe and effective treatment option for NMSC’ and ‘can be considered a first line treatment for NMSC for appropriately selected patients.’ Consistent with SkinCure Oncology’s advocacy for informed consent, the panel also recognized that ‘patients need to be offered all appropriate treatment options and should be a part of the decision-making process.'”

In January, the nation’s 100,000th patient was successfully treated with the GentleCure treatment, highlighting the increasing acceptance of this treatment option among dermatologists, Mohs surgeons and the public. “It was rewarding to hear how appreciative she was to have a noninvasive solution to her skin cancer challenge,” said Brandt.

In March, SkinCure Oncology announced the submission of its next-generation GentleBeam™ Image-Guided SRT technology to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. GentleBeam is designed to offer a gentle, targeted approach to treating nonmelanoma skin cancers, expanding nonsurgical options for both patients and healthcare providers. GentleBeam is not yet cleared by the FDA and is not available for commercial distribution in the United States.

“More than 500 dermatologists around the country offer the GentleCure Experience, and more than half of all practices offering GentleCure also provide Mohs surgery,” Brandt said. “With GentleCure’s high patient and physician satisfaction rates, it is clear that this noninvasive treatment option will be introduced in a great many more communities in the near future. Individuals with skin cancer can rest easy, knowing that the GentleCure Experience is readily available.”

About SkinCure Oncology

SkinCure Oncology is the industry leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure Experience™, Image-Guided SRT is available from some 500 physicians nationwide, with more than 100,000 patients having been treated. Learn more about the company at SkinCureOncology.com, and visit GentleCure.com for helpful consumer and patient information.

Media Contact:
Matt Russell
Russell Public Communications
520-232-9840
[email protected] 

SOURCE SkinCure Oncology